Patents by Inventor Damià Tormo Carulla
Damià Tormo Carulla has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11505526Abstract: An aryl-piperidine derivative of formula I, wherein the meaning of R3, X, Cz, and Cy is that specified in the description, for use as inhibitors of T cells.Type: GrantFiled: March 14, 2018Date of Patent: November 22, 2022Assignee: Artax Biopharma Inc.Inventors: Andrés Gagete Mateos, Damiá Tormo Carulla, Luc Marti Clauzel, Julio Castro Palomino
-
Patent number: 11434239Abstract: Aza-dihydro-acridone derivatives of formula I, wherein the meaning of R1, R?1, R2 and R3 is that specified in the description, to be used as T cells proliferation inhibitors.Type: GrantFiled: March 14, 2018Date of Patent: September 6, 2022Assignee: Artax Biopharma Inc.Inventors: Andrés Gagete Mateos, Damiá Tormo Carulla, Luc Marti Clauzel, Julio Castro Palomino
-
Publication number: 20200131125Abstract: An aryl-piperidine derivative of formula I, wherein the meaning of R3, X, Cz, and Cy is that specified in the description, for use as inhibitors of T cells.Type: ApplicationFiled: March 14, 2018Publication date: April 30, 2020Inventors: Andrés Gagete MATEOS, Damiá Tormo CARULLA, Luc Marti CLAUZEL, Julio Castro PALOMINO
-
Publication number: 20200079768Abstract: Aza-dihydro-acridone derivatives of formula I, wherein the meaning of R1, R?1, R2 and R3 is that specified in the description, to be used as T cells proliferation inhibitors.Type: ApplicationFiled: March 14, 2018Publication date: March 12, 2020Inventors: Andrés Gagete MATEOS, Damiá Tormo CARULLA, Luc Marti CLAUZEL, Julio Castro PALOMINO
-
Publication number: 20190134077Abstract: Process for the identification of compounds for treating cancer. The invention relates to a method for identifying candidate compounds for use as therapeutic agents for the treatment of cancer, among those who are able to activate the MDA-5 protein or increase NOXA protein levels and to trigger autophagy. It is based on the fact that activation of dsRNA sensor MDA-5 is able to trigger the destruction of cancer cells by activation both autophagy and apoptosis, autonomously and selectively in tumor cells, without provoking the stabilization of the natural antagonist NOXA, MCL-1. The invention also relates to the use of double-stranded RNAs of the same or similar nature such as polyinosinic-polycytidylic acid (pIC), complexed with carriers such as polyethylenimine polycation (PEI), for the manufacture of medicines for the treatment of cancer.Type: ApplicationFiled: September 12, 2018Publication date: May 9, 2019Applicant: FUNDACIÓN CENTRO NACIONAL DE INVESTIGACIONES ONCOLÓGICAS CARLOS IIIInventors: Maria Soledad SOENGAS GONZÁLEZ, Damiá TORMO CARULLA
-
Publication number: 20190117685Abstract: Process for the identification of compounds for treating cancer. The invention relates to a method for identifying candidate compounds for use as therapeutic agents for the treatment of cancer, among those who are able to activate the MDA-5 protein or increase NOXA protein levels and to trigger autophagy. It is based on the fact that activation of dsRNA sensor MDA-5 is able to trigger the destruction of cancer cells by activation both autophagy and apoptosis, autonomously and selectively in tumor cells, without provoking the stabilization of the natural antagonist NOXA, MCL-1. The invention also relates to the use of double-stranded RNAs of the same or similar nature such as polyinosinic-polycytidylic acid (pIC), complexed with carriers such as polyethylenimine polycation (PEI), for the manufacture of medicines for the treatment of cancer.Type: ApplicationFiled: December 11, 2018Publication date: April 25, 2019Applicant: FUNDACIÓN CENTRO NACIONAL DE INVESTIGACIONES ONCOLÓGICAS CARLOS IIIInventors: Maria Soledad SOENGAS GONZÁLEZ, Damiá TORMO CARULLA
-
Patent number: 10131647Abstract: The present invention relates to a group of compounds of formula (I) containing a chromene nucleus: and that present the capacity to inhibit the proliferation of lymphocytes mediated by the Nck interaction with TCR, so that the present invention also relates to the use of these compounds for the treatment of diseases or conditions where said interaction triggers a complication such as transplant rejection reactions, immune or autoimmune diseases, inflammatory diseases or proliferative diseases.Type: GrantFiled: October 20, 2014Date of Patent: November 20, 2018Assignee: Artex Biopharma Inc.Inventors: Andrés Gagete Mateos, Julio Castro Palomino, Luc Marti Clauzel, Damiá Tormo Carulla
-
Patent number: 10106518Abstract: The present invention relates to a group of compounds of formula (I) containing a chromene nucleus: and which present the ability to inhibit the lymphocytes proliferation mediated by the TCR interaction with Nck, so that the present invention also relates to the use of these compounds for the treatment of diseases or conditions wherein said interaction triggers a complication such as transplant rejection reactions, immune or autoimmune diseases, inflammatory diseases or proliferative diseases.Type: GrantFiled: October 20, 2014Date of Patent: October 23, 2018Assignee: Artax Biopharma Inc.Inventors: Andrés Gagete Mateos, Julio Castro Palomino, Luc Marti Clauzel, Damiá Tormo Carulla
-
Publication number: 20170020917Abstract: Process for the identification of compounds for treating cancer. The invention relates to a method for identifying candidate compounds for use as therapeutic agents for the treatment of cancer, among those who are able to activate the MDA-5 protein or increase NOXA protein levels and to trigger autophagy. It is based on the fact that activation of dsRNA sensor MDA-5 is able to trigger the destruction of cancer cells by activation both autophagy and apoptosis, autonomously and selectively in tumor cells, without provoking the stabilization of the natural antagonist NOXA, MCL-1. The invention also relates to the use of double-stranded RNAs of the same or similar nature such as polyinosinic-polycytidylic acid (pIC), complexed with carriers such as polyethylenimine polycation (PEI), for the manufacture of medicines for the treatment of cancer.Type: ApplicationFiled: March 23, 2016Publication date: January 26, 2017Inventors: Maria Soledad Soengas González, Damiá Tormo Carulla
-
Publication number: 20160244423Abstract: The present invention relates to a group of compounds of formula (I) containing a chromene nucleus: and that present the capacity to inhibit the proliferation of lymphocytes mediated by the Nck interaction with TCR, so that the present invention also relates to the use of these compounds for the treatment of diseases or conditions where said interaction triggers a complication such as transplant rejection reactions, immune or autoimmune diseases, inflammatory diseases or proliferative diseases.Type: ApplicationFiled: October 20, 2014Publication date: August 25, 2016Applicant: ARTAX BIOPHARMA INC.Inventors: Andrés Gagete Mateos, Julio Castro Palomino, Luc Marti Clauzel, Damiá Tormo Carulla
-
Publication number: 20140154202Abstract: Process for the identification of compounds for treating cancer. The invention relates to a method for identifying candidate compounds for use as therapeutic agents for the treatment of cancer, among those who are able to activate the MDA-5 protein or increase NOXA protein levels and to trigger autophagy. It is based on the fact that activation of dsRNA sensor MDA-5 is able to trigger the destruction of cancer cells by activation both autophagy and apoptosis, autonomously and selectively in tumor cells, without provoking the stabilization of the natural antagonist NOXA, MCL-1. The invention also relates to the use of double-stranded RNAs of the same or similar nature such as polyinosinic-polycytidylic acid (pIC), complexed with carriers such as polyethylenimine polycation (PEI), for the manufacture of medicines for the treatment of cancer.Type: ApplicationFiled: May 28, 2013Publication date: June 5, 2014Applicant: FUNDACIÓN CENTRO NACIONAL DE INVESTIGACIONES ONCOLÓGICAS CARLOS IIIInventors: María Soledad SOENGAS GONZÁLEZ, Damià TORMO CARULLA
-
Publication number: 20120172581Abstract: Process for the identification of compounds for treating cancer. The invention relates to a method for identifying candidate compounds for use as therapeutic agents for the treatment of cancer, among those who are able to activate the MDA-5 protein or increase NOXA protein levels and to trigger autophagy. It is based on the fact that activation of dsRNA sensor MDA-5 is able to trigger the destruction of cancer cells by activation both autophagy and apoptosis, autonomously and selectively in tumor cells, without provoking the stabilization of the natural antagonist NOXA, MCL-1. The invention also relates to the use of double-stranded RNAs of the same or similar nature such as polyinosinic-polycytidylic acid (pIC), complexed with carriers such as polyethylenimine polycation (PEI), for the manufacture of medicines for the treatment of cancer.Type: ApplicationFiled: July 5, 2010Publication date: July 5, 2012Applicant: FUNDACIÓN CENTRO NACIONAL DE INVESTIGACIONES ONCOLÓGICAS CARLOS IIIInventors: María Soledad Soengas González, Damià Tormo Carulla